A Case of Heparin-Induced Thrombocytopenia That Developed in the Therapeutic Course of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Table 2

Clinical characteristics of previously published four coexisting cases of anti-neutrophil cytoplasmic antibody-associated vasculitis and heparin-induced thrombocytopenia.

	Sex	Age	Type of ANCA	Type of organ injury	Treatment	Onset of HIT and type of heparin
Roe et al. [5]	M	65	PR3	Crescentic glomerulonephritis, pulmonary hemorrhage	mPSL pulse, PSL, CY, hemodialysis	9 days after the start of hemodialysis, unfractionated heparin
Kaneda et al. [6]	F	91	MPO	Kidney dysfunction, pulmonary hemorrhage	mPSL pulse, PSL, hemodialysis	13 days after the start of hemodialysis, unfractionated heparin
Mandai et al. [7]	M	40	MPO	Crescentic glomerulonephritis, interstitial pneumonia	mPSL pulse, PSL, CY, PE, hemodialysis	5 days after the start of hemodialysis, unfractionated heparin
Thong et al. [8]	M	71	PR3	Kidney dysfunction	mPSL pulse, PSL, CY, hemodialysis	15 days after the start of hemodialysis, unfractionated heparin and dalteparin

ANCA, anti-neutrophil cytoplasmic antibody; CY, cyclophosphamide therapy; F, female; HIT, heparin-induced thrombocytopenia; M, male; MPO, myeloperoxidase; mPSL, methylprednisolone; PE, plasma exchange therapy (including double filtration plasmapheresis); PR3, proteinase 3; PSL, prednisolone.